Home›Trial›NCT06588153
🔬NCT06588153Phase 4RECRUITING

A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China

Study Summary

The main objective of this study is to evaluate the efficacy of Prolia® in improving bone mass density (BMD) of lumbar spine at month 12.

Conditions
Glucocorticoid-induced Osteoporosis
Interventions / Drugs
Prolia®
View on ClinicalTrials.gov ↗
Sponsor
AMGN
Amgen Inc
Biologics
F33/100
Study Details
Enrollment100 participants
Primary Completion—
Lead SponsorAmgen
Data Retrieved2026-04-13 18:29:34.157986+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.